HGP0608 + HGP0816

HGP0608 + HGP0816 is a pharmaceutical combination evaluated in clinical trials for the treatment of hypertension and dyslipidemia, typically administered together with HGP0904. The combination includes HGP0608 (losartan, an angiotensin II receptor blocker/antihypertensive) and HGP0816 (rosuvastatin, an HMG-CoA reductase inhibitor/statin for cholesterol management). The main mechanism is the dual control of blood pressure and cholesterol, targeting cardiovascular risk reduction. Development and trials have been conducted primarily by Hanmi Pharmaceutical. The combination is not a fixed-dose product but rather the co-administration of these agents, sometimes alongside HGP0904 (amlodipine)[2][3].